Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.64 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2105091 | 0.98 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL3079356 | 0.84 | CYP11B1 (0.71) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6748340 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL27984850 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| Hydrochloric Acid SCHEMBL6599039 | 0.83 | CYP11B1 (0.50) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| Hydrochloric Acid SCHEMBL6923197 | 0.82 | CYP11B1 (0.49) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL6599693 | 0.82 | CYP11B1 (0.63) | CYP11B1CYP11B2IDO1 | |
| Hydrochloric Acid SCHEMBL6600110 | 0.81 | CYP19A1 (0.48) | CYP11B1CYP11B2IDO1 | |
| Hydrochloric Acid SCHEMBL6927344 | 0.81 | ALDH1A1 (0.48) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL9570444 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2IDO1HPGDSP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1081438-A | Imdazole derivatives and preparation method thereof and the application on therapeutics | FOURNIER IND & SANTE (FR) | 1994-02-02 | — | — | CN | claimed |
| CN-101374832-B | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | disclosed |
| US-8158668-B2 | Methods for treating CNS disorders with 4-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-1981880-B1 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-101374832-A | Use of 4-imidazole derivatives for CNS disorders | HOFFMANN LA ROCHE (CH) | 2009-02-25 | — | — | CN | disclosed |
| EP-1981880-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085556-A2 | USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-0005528-B1 | IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4208324-A | Disperse diaminopyridine-3-azo dyestuffs | CIBA-GEIGY CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4207324-A | DIURETICS, HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| EP-0005528-A2 | Imidazole derivatives, their preparation and pharmaceutical compositions | Takeda Chemical Industries, Ltd. (JP) | 1979-11-28 | — | — | EP | disclosed |
| US-4083847-A | Transiently water-soluble disperse mono-azo dyes containing a diamino-methylene-carbacyl group | CIBA-GEIGY CORPORATION (US) | 1978-04-11 | — | — | US | disclosed |
| US-4068085-A | YELLOW AND RED ON POLYESTERS AND ACRYLICS | CIBA-GEIGY CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-3987026-A | POLYESTERS | CIBA-GEIGY CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3945991-A | Heterocyclic azo compounds containing a quaternated hydrazide group | CIBA-GEIGY AG (CH) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197622-A1 | Methods for treating CNS disorders with 4-imidazole derivatives | CRY1, GPR119, MTNR1A | CYP11B1 11/4885CYP11B2 24/4885IDO1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.